SYS-CON MEDIA Authors: Greg Ness, Sean Houghton, Glenn Rossman, Ignacio M. Llorente, Xenia von Wedel

News Feed Item

New Research Highlights an Investigational Single-Entity Formulation Hydrocodone Bitartrate Extended-Release Tablet at PAINWeek

STAMFORD, Conn., Sept. 4, 2014 /PRNewswire/ -- Purdue Pharma is presenting results from several studies and post-hoc analyses evaluating extended-release, single-entity hydrocodone bitartrate tablets, including the analgesic effectiveness and safety among patients transitioning from immediate-release hydrocodone combination products and the formulation's abuse-deterrent potential  in recreational opioid abusers at PAINWeek national conference Sept. 2 – 6 in Las Vegas.

Purdue Pharma, L.P. logo.

Purdue Pharma's investigational pain medication, once-daily hydrocodone bitartrate (which is expected to be marketed under the trade name, Hysingla™ ER) is a single-entity product that does not include acetaminophen.  The tablets are formulated with abuse-deterrent properties designed to make the product more difficult to manipulate for the purpose of misuse or abuse by various routes of administration (e.g., chewing, snorting and intravenous injection).

Highlights of three of the several posters presented this week are as follows:

  • One poster, titled "Evaluation of once-daily hydrocodone (Hysingla™ ER) in users of immediate-release hydrocodone combination products," analyzed the analgesic effectiveness and safety of single-entity hydrocodone (Hysingla ER) in 20 mg to 120 mg tablets dosed once daily among patients with moderate to severe chronic pain and who were transitioning from hydrocodone  products that are combined with acetaminophen.  Data were from two phase 3 studies: a 12-week, placebo-controlled, double-blind study, and an open-label, long-term study with a 12-month maintenance treatment period. Among these patients in the placebo-controlled study, Hysingla ER (N=62) showed clinically meaningful and statistically significant pain relief at week 12 compared to placebo (N=67) in both primary and sensitivity analyses (deltas=0.64 to 0.98; P's = .0078 to .0357). Among patients in the long-term study, clinically significant improvements from baseline in pain relief (e.g., 30% reduction in pain) were achieved with Hysingla ER treatment, and these treatment effects were maintained throughout 12-month treatment period. Among patients who had previously used hydrocodone/acetaminophen products, adverse events were consistent with those associated with opioid analgesics. The most common treatment-emergent adverse events included constipation, nausea, vomiting, dizziness, and headache.
  • The next study, which is the first of two studies being presented on abuse potential, titled "Intranasal Abuse Potential Study of a Once-Daily, Single-Entity, Extended-Release Hydrocodone Tablet (Hysingla™ ER) in Recreational Opioid Users," compared the intranasal abuse potential of fine-milled and coarse-milled Hysingla ER (using an industrial mill and razor blade, respectively) to that of hydrocodone powder and placebo. Abuse potential was evaluated using pharmacokinetic measures of plasma samples and subjective pharmacodynamic measures of drug liking.
    • The pharmacokinetic data showed that subjects had a higher concentration of hydrocodone in the blood following hydrocodone powder than they did following use of either fine-milled or coarse-milled Hysingla.
    • The pharmacodynamic assessment showed that mean scores for overall drug liking were highest for hydrocodone powder followed by the two tampered Hysingla ER treatments and placebo. Compared with hydrocodone powder:
      • 68 percent of subjects using coarse-milled Hysingla ER had a reduction of at least 30 percent in drug liking where 64 percent had a reduction of at least 50 percent, and 44 percent had a reduction of at least 90 percent.
      • 72 percent of subjects using fine-milled Hysingla ER had a reduction of at least 30 percent in drug liking where 64 percent had a reduction of at least 50 percent, and 36 percent had a reduction of at least 90 percent.
  • The second of the two abuse-potential studies presented, titled "Oral Abuse Potential Study of a Once-Daily, Single-Entity, Extended-Release Hydrocodone Tablet (Hysingla™ ER) in Recreational Opioid Users," compared the oral abuse potential of Hysingla ER when chewed or when milled with an industrial mill to that of the intact Hysingla ER, immediate release hydrocodone solution and placebo. Abuse potential was evaluated using pharmacokinetic measures of plasma samples and subjective pharmacodynamic measures of drug liking.
    • The pharmacokinetic results showed higher concentrations of hydrocodone among subjects using immediate release hydrocodone solution than subjects using milled, chewed or intact Hysingla ER, and the  time to achieve maximum concentration was faster among subjects using hydrocodone IR than those using milled, chewed or intact Hysingla ER
    • The pharmacodynamic assessments showed that mean scores for overall drug liking were highest for hydrocodone IR solution and milled Hysingla ER. Compared to the hydrocodone IR solution:
      • 83 percent of subjects using intact Hysingla ER had a reduction of at least 30 percent in drug liking where 74 percent had a reduction of at least 50 percent, and 37 percent had a reduction of at least 90 percent.
      • 69 percent of subjects using chewed Hysingla ER had a reduction of at least 30 percent in drug liking where 60 percent had a reduction of at least 50 percent, and 29 percent had a reduction of at least 90 percent.
      • 17 percent of subjects using milled Hysingla ER had a reduction of at least 30 percent in drug liking where 9 percent had a reduction of at least 50 percent, and 6 percent had a reduction of at least 90 percent.

"These studies continue to support the fact that, if approved by the Food and Drug Administration, Hysingla ER could be an important alternative for healthcare professionals treating patients in chronic pain with a hydrocodone product formulated with physicochemical properties intended to deter abuse," said Todd Baumgartner, M.D., MPH, Vice President of Research & Development and Chief Medical Officer at Purdue Pharma which funded the research.

The opioid hydrocodone in combination with acetaminophen (Vicodin® and its generic formulations) is the most commonly prescribed opioid analgesics in the United States.1 However, acetaminophen may cause liver toxicity (i.e., hepatotoxicity), including serious liver failure, when a patient exceeds the total recommended dosage of less than 4g per day,2 prompting the need for an extended release option without acetaminophen.

Immediate release hydrocodone combination products are also the most widely abused (nonmedical use) according to the Substance Abuse and Mental Health Services Administration.3 Currently available hydrocodone formulations do not incorporate abuse-deterrent technologies. 

The U.S. Food and Drug Administration (FDA) recently granted Priority Review designation to Purdue's new drug application requesting approval to market Hysingla ER, which incorporates abuse-deterrent properties.

About Chronic Pain
Purdue is a leader in developing treatment options for the management of chronic pain, which is one of the most common reasons for visits to healthcare professionals. Chronic pain conditions affect more than 100 million U.S. adults and cost the American economy as much as $635 billion each year in direct healthcare expenses and lost productivity.

About Purdue Pharma L.P.
Purdue Pharma L.P. and its associated U.S. companies are privately-held pharmaceutical companies known for pioneering research on chronic pain. Headquartered in Stamford, CT, Purdue is engaged in the research, development, production, and distribution of both prescription and over-the-counter medicines and hospital products. Additional information about Purdue can be found at www.purduepharma.com.

1 U.S. Pharmaceutical Sales - Q4 2013, Drugs.com, Accessed 09/04/2014
2 Ferguson E, Nelson L. 2009. Silver Spring, MD: Food and Drug Administration. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM179888.pdf. Accessed 09/04/14.
3 2012 National Household Survey on Drug Use and Health, Table 1.89A, Substance Abuse and Mental Health Services Administration.  Accessed 09/04/2014

Logo - http://photos.prnewswire.com/prnh/20100921/NY67262

SOURCE Purdue Pharma L.P.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
15th Cloud Expo, which took place Nov. 4-6, 2014, at the Santa Clara Convention Center in Santa Clara, CA, expanded the conference content of @ThingsExpo, Big Data Expo, and DevOps Summit to include two developer events. IBM held a Bluemix Developer Playground on November 5 and ElasticBox held a Hackathon on November 6. Both events took place on the expo floor. The Bluemix Developer Playground, for developers of all levels, highlighted the ease of use of Bluemix, its services and functionalit...
SYS-CON Media announced today that Skytap blog on "DevOps Journal" exceeded 84,000 story reads. DevOps Journal is focused on this critical enterprise IT topic in the world of cloud computing. DevOps Journal brings valuable information to DevOps professionals who are transforming the way enterprise IT is done. Noel Wurst is the managing content editor at Skytap. Skytap provides SaaS-based dev/test environments to the enterprise. Skytap solution removes the inefficiencies and constraints that comp...
SYS-CON Events announced today that Gridstore™, the leader in hyper-converged infrastructure purpose-built to optimize Microsoft workloads, will exhibit at SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. Gridstore™ is the leader in hyper-converged infrastructure purpose-built for Microsoft workloads and designed to accelerate applications in virtualized environments. Gridstore’s hyper-converged infrastructure is the ...
In her General Session at 15th Cloud Expo, Anne Plese, Senior Consultant, Cloud Product Marketing, at Verizon Enterprise, focused on finding the right mix of renting vs. buying Oracle capacity to scale to meet business demands, and offer validated Oracle database TCO models for Oracle development and testing environments. Anne Plese is a marketing and technology enthusiast/realist with over 19+ years in high tech. At Verizon Enterprise, she focuses on driving growth for the Verizon Cloud platfo...
The 3rd International @ThingsExpo, co-located with the 16th International Cloud Expo - to be held June 9-11, 2015, at the Javits Center in New York City, NY - announces that it is now accepting Keynote Proposals. The Internet of Things (IoT) is the most profound change in personal and enterprise IT since the creation of the Worldwide Web more than 20 years ago. All major researchers estimate there will be tens of billions devices - computers, smartphones, tablets, and sensors - connected to th...
"There is a natural synchronization between the business models, the IoT is there to support ,” explained Brendan O'Brien, Co-founder and Chief Architect of Aria Systems, in this SYS-CON.tv interview at the 15th International Cloud Expo®, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
The Internet of Things promises to transform businesses (and lives), but navigating the business and technical path to success can be difficult to understand. In his session at @ThingsExpo, Sean Lorenz, Technical Product Manager for Xively at LogMeIn, demonstrated how to approach creating broadly successful connected customer solutions using real world business transformation studies including New England BioLabs and more.
The Internet of Things will greatly expand the opportunities for data collection and new business models driven off of that data. In her session at @ThingsExpo, Esmeralda Swartz, CMO of MetraTech, discussed how for this to be effective you not only need to have infrastructure and operational models capable of utilizing this new phenomenon, but increasingly service providers will need to convince a skeptical public to participate. Get ready to show them the money!
How do APIs and IoT relate? The answer is not as simple as merely adding an API on top of a dumb device, but rather about understanding the architectural patterns for implementing an IoT fabric. There are typically two or three trends: Exposing the device to a management framework Exposing that management framework to a business centric logic Exposing that business layer and data to end users. This last trend is the IoT stack, which involves a new shift in the separation of what stuff happe...
WebRTC defines no default signaling protocol, causing fragmentation between WebRTC silos. SIP and XMPP provide possibilities, but come with considerable complexity and are not designed for use in a web environment. In his session at @ThingsExpo, Matthew Hodgson, technical co-founder of the Matrix.org, discussed how Matrix is a new non-profit Open Source Project that defines both a new HTTP-based standard for VoIP & IM signaling and provides reference implementations.
"ElasticBox is an enterprise company that makes it very easy for developers and IT ops to collaborate to develop, build and deploy applications on any cloud - private, public or hybrid," stated Monish Sharma, VP of Customer Success at ElasticBox, in this SYS-CON.tv interview at DevOps Summit, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
The definition of IoT is not new, in fact it’s been around for over a decade. What has changed is the public's awareness that the technology we use on a daily basis has caught up on the vision of an always on, always connected world. If you look into the details of what comprises the IoT, you’ll see that it includes everything from cloud computing, Big Data analytics, “Things,” Web communication, applications, network, storage, etc. It is essentially including everything connected online from ha...
The Internet of Things is tied together with a thin strand that is known as time. Coincidentally, at the core of nearly all data analytics is a timestamp. When working with time series data there are a few core principles that everyone should consider, especially across datasets where time is the common boundary. In his session at Internet of @ThingsExpo, Jim Scott, Director of Enterprise Strategy & Architecture at MapR Technologies, discussed single-value, geo-spatial, and log time series dat...
An entirely new security model is needed for the Internet of Things, or is it? Can we save some old and tested controls for this new and different environment? In his session at @ThingsExpo, New York's at the Javits Center, Davi Ottenheimer, EMC Senior Director of Trust, reviewed hands-on lessons with IoT devices and reveal a new risk balance you might not expect. Davi Ottenheimer, EMC Senior Director of Trust, has more than nineteen years' experience managing global security operations and asse...
SYS-CON Events announced today Isomorphic Software, the global leader in high-end, web-based business applications, will exhibit at SYS-CON's DevOps Summit 2015 New York, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. Isomorphic Software is the global leader in high-end, web-based business applications. We develop, market, and support the SmartClient & Smart GWT HTML5/Ajax platform, combining the productivity and performance of traditional desktop software ...